Skip to main content
SpringerLink
Log in

Prominin-1 (CD133) and Metastatic Melanoma: Current Knowledge and Therapeutic Perspectives

  • Chapter
  • First Online:
Prominin-1 (CD133): New Insights on Stem & Cancer Stem Cell Biology

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 777))

Abstract

Innovative approaches to specifically target the melanoma subpopulation responsible for local invasion and metastatic dissemination are needed. Prominin-1 (CD133) expression has been observed in many melanoma cell lines, as well as in primary and metastatic melanomas from patients. Although its function(s) in melanoma is presently unknown, prominin-1 may represent a molecular target, due to its association with melanoma stem cells and with the metastatic phenotype.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60:277–300

    Article  PubMed  Google Scholar 

  2. Tsai J, Lee JT, Wang W et al (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 105:3041–3046

    Article  PubMed  CAS  Google Scholar 

  3. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, Tahan SR (2007) Increased expression of stem cell markers in malignant melanoma. Mod Pathol 20:102–107

    Article  PubMed  CAS  Google Scholar 

  4. Frank NY, Margaryan A, Huang Y et al (2005) ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 65:4320–4333

    Article  PubMed  CAS  Google Scholar 

  5. Monzani E, Facchetti F, Galmozzi E et al (2007) Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43:935–946

    Article  PubMed  CAS  Google Scholar 

  6. Rappa G, Fodstad O, Lorico A (2008) The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 26:3008–3017

    Article  PubMed  CAS  Google Scholar 

  7. Mizrak D, Brittan M, Alison MR (2008) CD133: molecule of the moment. J Pathol 214:3–9

    Article  PubMed  CAS  Google Scholar 

  8. Grichnik JM, Burch JA, Schulteis RD et al (2006) Melanoma, a tumor based on a mutant stem cell? J Invest Dermatol 126:142–153

    Article  PubMed  CAS  Google Scholar 

  9. Belicchi M, Pisati F, Lopa R et al (2004) Human skin-derived stem cells migrate throughout forebrain and differentiate into astrocytes after injection into adult mouse brain. J Neurosci Res 77:475–486

    Article  PubMed  CAS  Google Scholar 

  10. Bevona C, Goggins W, Quinn T, Fullerton J, Tsao H (2003) Cutaneous melanomas associated with nevi. Arch Dermatol 139:1620–1624, discussion 4

    Article  PubMed  Google Scholar 

  11. Zabierowski SE, Herlyn M (2008) Melanoma stem cells: the dark seed of melanoma. J Clin Oncol 26:2890–2894

    Article  PubMed  Google Scholar 

  12. Boiko AD, Razorenova OV, van de Rijn M et al (2011) Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 466:133–137

    Article  Google Scholar 

  13. Fang D, Nguyen TK, Leishear K et al (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65:9328–9337

    Article  PubMed  CAS  Google Scholar 

  14. Mihic-Probst D, Kuster A, Kilgus S et al (2007) Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int J Cancer 121:1764–1770

    Article  PubMed  CAS  Google Scholar 

  15. Quintana E, Shackleton M, Foster HR et al (2010) Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18:510–523

    Article  PubMed  CAS  Google Scholar 

  16. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ (2008) Efficient tumour formation by single human melanoma cells. Nature 456:593–598

    Article  PubMed  CAS  Google Scholar 

  17. Scharenberg CW, Harkey MA, Torok-Storb B (2002) The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99:507–512

    Article  PubMed  CAS  Google Scholar 

  18. Gil-Benso R, Monteagudo C, Cerda-Nicolas M et al (2012) Characterization of a new human melanoma cell line with CD133 expression. Hum Cell 25:61–67

    Article  PubMed  CAS  Google Scholar 

  19. Pietra G, Manzini C, Vitale M et al (2009) Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol 21:793–801

    Article  PubMed  CAS  Google Scholar 

  20. Kim M, Koh YJ, Kim KE et al (2010) CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Res 70:10411–10421

    Article  PubMed  CAS  Google Scholar 

  21. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P (1997) Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275:1790–1792

    Article  PubMed  CAS  Google Scholar 

  22. Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER (1999) Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol 154:325–329

    Article  PubMed  CAS  Google Scholar 

  23. Damsky WE, Curley DP, Santhanakrishnan M et al (2011) beta-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 20:741–754

    Article  PubMed  CAS  Google Scholar 

  24. Horst D, Kriegl L, Engel J, Jung A, Kirchner T (2009) CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer. Eur J Cancer 45:2034–2040

    Article  PubMed  CAS  Google Scholar 

  25. Boivin D, Labbe D, Fontaine N et al (2009) The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases. Biochemistry 48:3998–4007

    Article  PubMed  CAS  Google Scholar 

  26. Katoh Y, Katoh M (2007) Comparative genomics on PROM1 gene encoding stem cell marker CD133. Int J Mol Med 19:967–970

    PubMed  CAS  Google Scholar 

  27. Bongiorno MR, Doukaki S, Malleo F, Arico M (2008) Identification of progenitor cancer stem cell in lentigo maligna melanoma. Dermatol Ther 21(Suppl 1):S1–S5

    Article  PubMed  Google Scholar 

  28. Piras F, Perra MT, Murtas D et al (2010) The stem cell marker nestin predicts poor prognosis in human melanoma. Oncol Rep 23:17–24

    PubMed  Google Scholar 

  29. Gazzaniga P, Cigna E, Panasiti V et al (2010) CD133 and ABCB5 as stem cell markers on sentinel lymph node from melanoma patients. Eur J Surg Oncol 36:1211–1214

    Article  PubMed  CAS  Google Scholar 

  30. Sztiller-Sikorska M, Koprowska K, Jakubowska J et al (2012) Sphere formation and self-renewal capacity of melanoma cells is affected by the microenvironment. Melanoma Res 22:215–224

    Article  PubMed  Google Scholar 

  31. Fusi A, Reichelt U, Busse A et al (2011) Expression of the stem cell markers nestin and CD133 on circulating melanoma cells. J Invest Dermatol 131:487–494

    Article  PubMed  CAS  Google Scholar 

  32. Thill M, Berna MJ, Grierson R et al (2011) Expression of CD133 and other putative stem cell markers in uveal melanoma. Melanoma Res 21:405–416

    Article  PubMed  CAS  Google Scholar 

  33. Kupas V, Weishaupt C, Siepmann D et al (2011) RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells. J Invest Dermatol 131:944–955

    Article  PubMed  CAS  Google Scholar 

  34. Sharma BK, Manglik V, Elias EG (2010) Immuno-expression of human melanoma stem cell markers in tissues at different stages of the disease. J Surg Res 163:e11–e15

    Article  PubMed  CAS  Google Scholar 

  35. Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29:4741–4751

    Article  PubMed  CAS  Google Scholar 

  36. Diehn M, Cho RW, Lobo NA et al (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458:780–783

    Article  PubMed  CAS  Google Scholar 

  37. Smith LM, Nesterova A, Ryan MC et al (2008) CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 99:100–109

    Article  PubMed  CAS  Google Scholar 

  38. Siva AC, Wild MA, Kirkland RE et al (2008) Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model. Cancer Res 68:3759–3766

    Article  PubMed  CAS  Google Scholar 

  39. Foehr ED, Lorente G, Kuo J, Ram R, Nikolich K, Urfer R (2006) Targeting of the receptor protein tyrosine phosphatase beta with a monoclonal antibody delays tumor growth in a glioblastoma model. Cancer Res 66:2271–2278

    Article  PubMed  CAS  Google Scholar 

  40. Wargalla UC, Reisfeld RA (1989) Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells. Proc Natl Acad Sci USA 86:5146–5150

    Article  PubMed  CAS  Google Scholar 

  41. Yin AH, Miraglia S, Zanjani ED et al (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90:5002–5012

    PubMed  CAS  Google Scholar 

  42. Bühring HJ, Seiffert M, Marxer A et al (1999) AC133 antigen expression is not restricted to acute myeloid leukemia blasts but is also found on acute lymphoid leukemia blasts and on a subset of CD34+ B-cell precursors. Blood 94:832–833

    PubMed  Google Scholar 

  43. Gallacher L, Murdoch B, Wu DM, Karanu FN, Keeney M, Bhatia M (2000) Isolation and characterization of human CD34(−)Lin(−) and CD34(+)Lin(−) hematopoietic stem cells using cell surface markers AC133 and CD7. Blood 95:2813–2820

    PubMed  CAS  Google Scholar 

  44. de Wynter EA, Buck D, Hart C et al (1998) CD34  +  AC133+ cells isolated from cord blood are highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors. Stem Cells 16:387–396

    Article  PubMed  Google Scholar 

  45. Karbanová J, Missol-Kolka E, Fonseca A-V et al (2008) The stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia. J Histochem Cytochem 56:977–993

    Article  PubMed  Google Scholar 

  46. Christiansen J, Rajasekaran AK (2004) Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol Cancer Ther 3:1493–1501

    PubMed  CAS  Google Scholar 

  47. Miyabayashi T, Kagamu H, Koshio J et al (2011) Vaccination with CD133(+) melanoma induces specific Th17 and Th1 cell-mediated antitumor reactivity against parental tumor. Cancer Immunol Immunother 60:1597–1608

    Article  PubMed  Google Scholar 

  48. Bauer N, Wilsch-Bräuninger M, Karbanová J et al (2011) Haematopoietic stem cell differentiation promotes the release of prominin-1/CD133-containing membrane vesicles-a role of the endocytic-exocytic pathway. EMBO Mol Med 3:398–409

    Article  PubMed  CAS  Google Scholar 

  49. Fargeas CA, Karbanová J, Jászai J, Corbeil D (2011) CD133 and membrane microdomains – Old facets for future hypotheses. World J Gastroenterol 17:4149–4152

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by US NIH R01CA133797 (G. R.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. The authors declare to have no conflict of interests. The authors thank H. Rosenberg and R. R. Fiscus for their support.

Author information

Authors and Affiliations

  1. Cancer Research Program, Roseman University of Health Sciences, 89104, Henderson, NV, USA

    Aurelio Lorico, Javier Mercapide & Germana Rappa

  2. College of Pharmacy, Roseman University of Health Sciences, 89104, Henderson, NV, USA

    Aurelio Lorico & Germana Rappa

Authors
  1. Aurelio Lorico
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Javier Mercapide
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Germana Rappa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aurelio Lorico .

Editor information

Editors and Affiliations

  1. , Biotechnological Centre (BIOTEC), Dresden University of Technology, Fetscherstr. 74, Dresden, 01307, Sachsen, Germany

    Denis Corbeil

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Lorico, A., Mercapide, J., Rappa, G. (2013). Prominin-1 (CD133) and Metastatic Melanoma: Current Knowledge and Therapeutic Perspectives. In: Corbeil, D. (eds) Prominin-1 (CD133): New Insights on Stem & Cancer Stem Cell Biology. Advances in Experimental Medicine and Biology, vol 777. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5894-4_13

Download citation

Publish with us

Policies and ethics

Search

Navigation